Elsevier

Gynecologic Oncology

Volume 129, Issue 1, April 2013, Pages 107-112
Gynecologic Oncology

Bowel obstruction in elderly ovarian cancer patients: A population-based study

https://doi.org/10.1016/j.ygyno.2012.12.028Get rights and content

Abstract

Purpose

Bowel obstruction is a common pre-terminal event in abdominal/pelvic cancer that has mainly been described in small single-institution studies. We used a large, population-based database to investigate the incidence, management, and outcomes of obstruction in ovarian cancer patients.

Patients and methods

We identified patients with stages IC–IV ovarian cancer, aged 65 years or older, in the Surveillance, Epidemiology and End Results (SEER)-Medicare database diagnosed between January 1, 1991 and December 31, 2005. We modeled predictors of inpatient hospitalization for bowel obstruction after cancer diagnosis, categorized management of obstruction, and analyzed the associations between treatment for obstruction and outcomes.

Results

Of 8607 women with ovarian cancer, 1518 (17.6%) were hospitalized for obstruction subsequent to cancer diagnosis. Obstruction at cancer diagnosis (HR = 2.17, 95%CI: 1.86–2.52) and mucinous tumor histology (HR = 1.45, 95%CI: 1.15–1.83) were associated with increased risk of subsequent obstruction. Surgical management of obstruction was associated with lower 30-day mortality (13.4% in women managed surgically vs. 20.2% in women managed non-surgically), but equivalent survival after 30 days and equivalent rates of post-obstruction chemotherapy. Median post-obstruction survival was 382 days in women with obstructions of adhesive origin and 93 days in others.

Conclusion

In this large-scale, population-based assessment of patients with advanced ovarian cancer, nearly 20% of women developed bowel obstruction after cancer diagnosis. While obstruction due to adhesions did not signal the end of life, all other obstructions were pre-terminal events for the majority of patients regardless of treatment.

Highlights

► Bowel obstruction in 17% of ovarian cancer patients in population based sample ► Post-obstruction survival 382 days for those with adhesions versus 93 days in others ► No increase in survival with surgery except for those with adhesions

Introduction

Death due to cancer can involve painful and care-intensive complications, demanding palliative treatments sensitive to patient needs. One such complication is bowel obstruction, wherein recurrent abdominal or pelvic cancer leads to a blocked intestinal tract, which in turn results in nausea, vomiting, and dehydration [1]. Obstruction usually requires inpatient hospitalization [2], [3] and may be the proximal cause of death [4], [5]. Bowel obstruction is particularly common in advanced ovarian cancer patients, with estimates of lifetime incidence ranging up to 35% [6], [7], [8].

Obstruction management options can be broadly categorized into surgical treatments, such as bypasses or colostomies, and non-surgical treatments, such as bowel rest with decompression, pharmacological management, or endoscopic placement of a stent at the obstruction site [9]. There exist no formal guidelines for treatment [3], in part because some studies have found surgery to be associated with improved survival [4], [7], [10] while others have found no survival benefit to surgery or attribute minor survival differences to patient selection [6], [11].

To date, most studies of bowel obstruction management and outcomes in the context of recurrent ovarian cancer have been hospital-based and had small sample sizes [4], [5], [6], [7], [8], [10], [11], [12], [13], [14], [15]. In this study, we estimate the incidence of obstruction in a population-based sample of ovarian cancer patients, using the Surveillance, Epidemiology and End Results (SEER) and Medicare claim linked databases [16]. We also investigate factors associated with bowel obstruction, treatment of bowel obstruction, and outcomes after a hospitalization for obstruction.

Section snippets

Data source

We analyzed data from the Surveillance, Epidemiology, and End Results (SEER)–Medicare database, which links SEER's detailed registry data with Medicare claims data [17]. The SEER database contains records of patients diagnosed with cancer in regions that contain approximately 14% of the US population; in 2000, this database was expanded to include approximately 26% of the US population [18].

Cohort selection

We selected women who had a pathologically confirmed first and primary diagnosis of stage IC, II, III,

Characteristics of surgical treatment for bowel obstruction

We considered a physician or hospital claim for gastroenterostomy, entero-enterostomy, bowel resection, enterostomy, and lysis of peritoneal adhesions (codes provided online in Appendix 1) to represent surgical therapy. We did not consider an isolated claim for laparotomy or laparoscopy to constitute surgical therapy in the absence of secondary procedure codes because it is unclear whether surgical correction of the obstruction was attempted.

Outcomes

We used hospital claim files to calculate length of stay and considered horizontal transfers to another acute care hospital part of the same hospitalization. For each patient who had died at the time of last follow-up, we calculated days of life remaining after first post-diagnosis obstruction. We examined all Medicare hospital claims that post-dated the initial claim for obstruction to assess hospital re-admission rates, post obstruction chemotherapy rates, and to compute a ratio of days in to

Statistical analysis

We used univariable Cox proportional hazards models to assess predictors of time to hospitalization for bowel obstruction and post-obstruction survival. We used Kaplan–Meier curves to compute survival times, median time to obstruction and length of hospital stay. Time-to-obstruction models used date of PTR or cancer diagnosis (if no PTR) as time 0, and treated both death and loss to follow-up as censoring events. The assumption of proportionality was assessed visually. All statistical tests

Results

We identified 8663 women ≥ 65 years old diagnosed with stages IC–IV ovarian carcinoma. We excluded 56 women who had a diagnosis of bowel obstruction prior to the cancer diagnosis. The final cohort was composed of 8607 women, 6966 (80.9%) of whom had died by the time of last follow-up. Of the final cohort, 1518 (17.6%) were hospitalized for bowel obstruction at least once between cancer diagnosis and end of follow-up, including 1357 (19.5%) of those who had died. Among the 1518 hospitalized for

Discussion

In this study of 8607 women diagnosed with ovarian cancer after age 65, 19.5% of those followed from diagnosis to death were hospitalized for bowel obstruction subsequent to their cancer diagnosis. Subsequent obstruction was associated with mucinous tumor histology, younger age, earlier year of diagnosis and history of obstruction at time of cancer diagnosis. About 1 in 4 obstructions were managed surgically, and the median survival after obstruction was poor unless the obstruction appeared to

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Source of funding

This study was supported in part by a fellowship from NCI (R25 CA094061) to MW and a fellowship from NCI (T32 CA09529) to SJM.

References (39)

  • G. Mangili

    Octreotide in the management of bowel obstruction in terminal ovarian cancer

    Gynecol Oncol

    (1996)
  • N.M. Foster

    Small bowel obstruction: a population-based appraisal

    J Am Coll Surg

    (2006)
  • C.I. Ripamonti et al.

    Management of malignant bowel obstruction

    Eur J Cancer

    (2008)
  • C. Ripamonti et al.

    Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer

    Support Care Cancer

    (2001)
  • R. DeBernardo

    Surgical management of malignant bowel obstruction: strategies toward palliation of patients with advanced cancer

    Curr Oncol Rep

    (2009)
  • D.N. Bryan

    An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer

    Int J Gynecol Cancer

    (2006)
  • G. Mangili

    Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis

    Int J Gynecol Cancer

    (2005)
  • A. Kucukmetin

    Palliative surgery versus medical management for bowel obstruction in ovarian cancer

    Cochrane Database Syst Rev

    (2010)
  • A. Gadducci

    Survival after intestinal obstruction in patients with fatal ovarian cancer: analysis of prognostic variables

    Int J Gynecol Cancer

    (1998)
  • Cited by (40)

    • Supported self-management as a model for end-of-life care in the setting of malignant bowel obstruction: A qualitative study

      2020, Gynecologic Oncology
      Citation Excerpt :

      Malignant bowel obstruction (MBO) is a common but devastating and highly symptomatic complication of gynecologic cancer that signals a transition to the end-of-life, with survival ranging from weeks to months [1–5]. Despite its known trajectory, existing care is typically reactive: 40% of ovarian cancer patients with MBO undergo repeated admissions [3–6], 5% receive palliative care consultations on their index stay [4], and 25% die in hospital [7]. Many experience marginalization, social isolation, and abandonment [8].

    • Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome?

      2019, Gynecologic Oncology
      Citation Excerpt :

      It showed that uterine cancer origin (as well as age, race, ability to undergo surgery, receiving chemotherapy after MBO, and initial albumin) were independently associated with survival after MBO. Our study supports previous evidence that a diagnosis of MBO from recurrent/progressive gynecologic cancer is an end-of-life state [3,4,5,6], with overall median survival of 105 days. Women with uterine cancer in our cohort had a median survival after MBO diagnosis that was less than half that of their ovarian cancer counterparts (57 days vs 131 days) despite the fact that a smaller percentage presented with advanced stage disease and they had fewer previous chemotherapy regimens.

    View all citing articles on Scopus

    Data in this manuscript has not been presented previously.

    View full text